First-in-class oral mechanism triggers natural satiety hormones, addressing key limitations of GLP-1 therapiesPhase I data demonstrate fat mass reduction, preservation of lean mass, 80% responder rate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results